Skip to main content

Biosimilars for RA

Course Videos

Showing 37 - 46 of 46 results

Previous| 1 | 2 | 3 | 4 |Next

What clinical scenarios and patient types with RA and related diseases can you imagine where the use of a biosimilar-- INFLIXIMAB-DYYB or others--makes good pharmacoeconomic and clinical sense? Video

What clinical scenarios and patient types with RA and related diseases can you imagine where the use of a biosimilar-- INFLIXIMAB-DYYB or others--makes good pharmacoeconomic and clinical sense?

What clinical scenarios and patient types with RA and related diseases can you imagine where the use of a biosimilar— INFLIXIMAB-DYYB or others—makes good pharmacoeconomic and clinical sense, as opposed to using the reference brand product, ...

Why would specialists use biosimilars? Can you discuss how rheumatologists and pharmacists make cost reduction-based clinical decisions when selecting anti-TNF biologics in the setting of RA, AS, psoriatic arthritis and related conditions? Video

Why would specialists use biosimilars? Can you discuss how rheumatologists and pharmacists make cost reduction-based clinical decisions when selecting anti-TNF biologics in the setting of RA, AS, psoriatic arthritis and related conditions?

Why would specialists want to use biosimilars in their practice? Can you discuss how rheumatologists and pharmacists should make important cost reduction-based clinical decisions when selecting anti-TNF biologics, based on primary differences ...

Once analytics, pharmacokinetics, pharmacodynamics, and clinical trials confirm the clinical value and safety of the biosimilar, how does this translate into cost savings? Video

Once analytics, pharmacokinetics, pharmacodynamics, and clinical trials confirm the clinical value and safety of the biosimilar, how does this translate into cost savings?

Once robust analytics, pharmacokinetics, pharmacodynamics, and clinical trials confirm the clinical value and safety of the biosimilar, how does this translate into cost savings for patients and healthcare institutions?

After physicochemical criteria are met, what kind of clinical trials, with what end points and safety profiles must be achieved for regulatory agencies to approve biosimilars? Video

After physicochemical criteria are met, what kind of clinical trials, with what end points and safety profiles must be achieved for regulatory agencies to approve biosimilars?

After physicochemical criteria are met, what kind of clinical trials, with precisely what end points and safety profiles must be achieved for regulatory agencies to approve biosimilars, and for what range of indications can such approvals be made?

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications? Video

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications?

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications? Can you differentiate based on the specific steps of the approval process, evaluation, clinical trials required, ...

Can you discuss study design, rationale, results, and implications of recent trials focused on anti-TNF biosimilars in the setting of RA, AS, and related conditions? Video

Can you discuss study design, rationale, results, and implications of recent trials focused on anti-TNF biosimilars in the setting of RA, AS, and related conditions?

Can you discuss and explain the study design, rationale, results, and clinical implications of the most recent clinical evidence — i.e. clinical trials — focused on the safety and efficacy of approved biosimilar therapies, such as INFLIXIMAB-DYYB ...

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications? Video

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications?

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications?

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications? Video

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications?

How do regulatory approval and evaluation processes for biosimilars differ from those used for small-molecule generic medications?

Can you discuss and explain the study design, rationale, results, and clinical implications of the most recent clinical evidence — i.e. clinical trials — focused on the safety and efficacy of approved biosimilar therapies, such as INFLIXIMAB-DYYB (IN Video

Can you discuss and explain the study design, rationale, results, and clinical implications of the most recent clinical evidence — i.e. clinical trials — focused on the safety and efficacy of approved biosimilar therapies, such as INFLIXIMAB-DYYB (IN

Can you discuss and explain the study design, rationale, results, and clinical implications of the most recent clinical evidence — i.e. clinical trials — focused on the safety and efficacy of approved biosimilar therapies, such as INFLIXIMAB-DYYB (IN

Can you discuss and explain the study design, rationale, results, and practical clinical implications of the most recent clinical evidence focused on anti-TNF inhibitor biosimilars for infliximab in the setting of RA; and by extrapolation, AS,... Video

Can you discuss and explain the study design, rationale, results, and practical clinical implications of the most recent clinical evidence focused on anti-TNF inhibitor biosimilars for infliximab in the setting of RA; and by extrapolation, AS,...

Can you discuss and explain the study design, rationale, results, and practical clinical implications of the most recent clinical evidence focused on anti-TNF inhibitor biosimilars for infliximab in the setting of RA; and by extrapolation, AS,...

Showing 37 - 46 of 46 results

Previous| 1 | 2 | 3 | 4 |Next